Latest News of GLP
DR. MARC SIEGEL: Why Ozempic, Wegovy and other GLP-1s could be a magic shot against alcohol abuse
By Fox News |
4 days ago
By agreeing to Fox News' terms, you consent to financial incentive disclosures. A study shows GLP-1 drugs like semaglutide can reduce alcohol-related hospitalizations, offering hope for those with Alc...
From GLP-1 Drugs To Catastrophic Claims - Why Employer Health Premiums Are Skyrocketing In 2025
By Yahoo! Finance |
1 week ago
Health insurance premiums are expected to rise significantly in 2025 due to factors like increased adoption of GLP-1 drugs and rising catastrophic claims. Employers, especially smaller ones, may face ...
Is Gaming and Leisure Properties, Inc. (GLPI) the Most Promising Gambling Stock in 2024?
By Yahoo! Finance |
2 weeks ago
The global gambling market is projected to grow significantly, with factors like legalization, urbanization, and sports betting driving the industry. Las Vegas remains a key player, with strong touris...
-
Hims & Hers Health jumps on earnings. CFO talks GLP-1 influences.
By Yahoo! Finance | 2 weeks agoHims & Hers Health (HIMS) saw a rise in shares post better Q3 revenue and raised outlook. The CFO, Yemi Okupe, mentioned a 77% revenue increase, strong EBITDA margins, and 2 million consumers on the p...
-
Hims & Hers shares rally on results, despite continued GLP-1 drug shortage
By MarketWatch | 2 weeks agoHims & Hers Health Inc. saw a surge in shares after raising its sales outlook due to increased demand for personalized care and weight-loss drugs. Despite popularity, drug shortages and competition re...
-
Hims & Hers Health Faces Pressure Ahead of Earnings Amid Eli Lilly's GLP-1 News
By Yahoo! Finance | 3 weeks agoHims & Hers Health, Inc. (NYSE:HIMS) faces stock decline due to Eli Lilly's (NYSE:LLY) GLP-1 revenue miss. Concerns arise over Hims' compounded GLP-1 offerings....
-
Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution?
By Yahoo! Finance | 3 weeks agoThe healthcare industry is abuzz with GLP-1 agonists like Ozempic and Wegovy for treating diabetes and obesity. Viking Therapeutics is a key player with potential in the weight loss market, particular...
-
Gaming and Leisure Properties Inc (GLPI) Q3 2024 Earnings Call Highlights: Strong Real Estate ...
By Yahoo! Finance | 4 weeks agoBrandon Moore confirmed that the lease will have escalators, with specific incentives for extending confidential. The 45-year lease maximum aims to ensure good REIT income. CEO Peter Carlino is open t...
-
Decoding Gaming and Leisure Properties Inc (GLPI): A Strategic SWOT Insight
By Yahoo! Finance | 4 weeks agoGaming and Leisure Properties Inc (NASDAQ:GLPI) faces threats like economic downturns and increased competition in the gaming sector. Despite challenges, GLPI's strengths include a robust real estate ...
-
Eli Lilly (LLY): Dominating the GLP-1 Market with Innovative Treatments
By Yahoo! Finance | 4 weeks agoThe US economy is predicted to have a soft landing after a 50 basis point Fed rate cut in September 2024. Despite concerns about a recession, improving economic indicators like job growth and stable g...
-
GLP's Sale of Stake in China Operations Is Said to Have Stalled
By Yahoo! Finance | 4 weeks agoNegotiations between GLP Pte and Guangdong Holdings Ltd. for the sale of a stake in GLP's China operations have stalled due to disagreements over deal terms. GLP may explore other options as talks wit...
-
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move
By Yahoo! Finance | 1 month agoHealthcare companies are eyeing the $200 billion GLP-1 weight loss drug market, but Novartis is avoiding the competition. Instead, focusing on cancer therapies and neurodegenerative diseases, offering...
-
GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom
By Yahoo! Finance | 1 month agoWeight loss drugs targeting GLP-1 receptors like Zepbound and Wegovy are popular, but other companies offer innovative alternatives. Zealand Pharma's petrelintide activates amylin and calcitonin recep...
-
GLP-1 drug shortage sparks legal action
By POLITICO | 1 month agoThe FDA faces legal challenges over GLP-1 shortages amid disputes between Eli Lilly and compounding pharmacists. FDA's flexibility and legal constraints in enforcing compounder regulations, and Lilly'...
-
WeightWatchers stock rallies 170%! But new compounded GLP-1 drug is 'not a sustainable long-term business model.'
By Yahoo! Finance | 1 month agoWeightWatchers is venturing into the weight-loss drug market to revitalize its struggling business, with a recent surge in stock value. By offering compounded GLP-1 drugs, the company aims to compete ...